Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Enhancing the sequential flamsa-treosulfan conditioning regimen with venetoclax – first results from the multicenter flamsaclax Phase I/II trial

Felicitas Schulz, Udo Holtick, Mareike Verbeek, Edgar Jost, Gesine Bug, Inken Hilgendorf, Nadja Drusenheimer, Christof Scheid, Peter Herhaus, Kathrin Nachtkamp, Paul Jäger, Norbert Gattermann, Sascha Dietrich, Ulrich Germing, Guido Kobbe

Blood (2025) 146 (Supplement 1): 5992.

https://doi.org/10.1182/blood-2025-5992

Published: 2025

Journal Articles

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

Krischan Braitsch, Karin Huber, Andrew Berdel, Lydia Kretschmer, Adrian Gottschlich, Tim Lohmann, Kathrin Rieger, Karsten Spiekermann, Thomas Schroeder, Silke Kapp-Schwoerer, Mareike Verbeek, Florian Bassermann, Hartmut Döhner, Tim Sauer, Christoph Röllig, Jan-Henrik Mikesch, Franziska Westendorf, Lars Fransecky, Katharina S. Götze

Blood (2025) 146 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2025-2846

Published: 2025

Journal Articles

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.

Blood (2025) 146 (Supplement 1): 6011.

https://doi.org/10.1182/blood-2025-6011

Published: 2025

Journal Articles

Multicenter Phase II trial of enasidenib as maintenance treatment following allogeneic stem cell transplantation in IDH2-mutated myeloid neoplasms – the IDH2-post-allo-trial (NCT04522895)

Thomas Schroeder, Matthias Stelljes, Edgar Jost, Jan Moritz Middeke, Gesine Bug, Georg-Nikolaus Franke, Udo Holtick, Christof Scheid, Mareike Verbeek, Caroline Pabst, Hans Christian Reinhardt, Johannes Schetelig, Nicolaus Kröger, Nadja Drusenheimer, Christina Rautenberg, Guido Kobbe

Blood (2025) 146 (Supplement 1): 4302.

https://doi.org/10.1182/blood-2025-4302

Published: 2025

Journal Articles

The role of microbial metabolites in fecal microbiota transplantation in patients with acute gvhd of the gut

Blood (2025) 146 (Supplement 1): 4236.

https://doi.org/10.1182/blood-2025-4236

Published: 2025

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Blood (2024) 144 (Supplement 1): 3554.

https://doi.org/10.1182/blood-2024-204560

Published: 2024

Journal Articles

Omitting Ciprofloxacin Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Does Not Result in Inferior Outcomes

Krischan Braitsch, Vanessa Nehrbaß, Katharina Nickel, Maike Hefter, Katrin Koch, Kathrin Rothe, Florian Bassermann, Jochen Schneider, Katharina S. Götze, Peter Herhaus, Mareike Verbeek

Blood (2024) 144 (Supplement 1): 3513.

https://doi.org/10.1182/blood-2024-210620

Published: 2024

Journal Articles

Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes

Blood (2024) 144 (Supplement 1): 780.

https://doi.org/10.1182/blood-2024-199035

Published: 2024

Journal Articles

Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 4904.

https://doi.org/10.1182/blood-2024-193273

Published: 2024

Journal Articles

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2024-203487

Published: 2024

Journal Articles

Real-World Data Suggest Effectiveness of Allogeneic Mesenchymal Stromal (MSC-FFM) Cells in Ruxolitinib-Refractory Acute Graft-Versus-Host Disease

Blood (2023) 142 (Supplement 1): 4927.

https://doi.org/10.1182/blood-2023-174492

Published: 2023

Journal Articles

Bacterial and Bacteriophage Consortia Are Associated with Protective Intestinal Immuno-Modulatory Metabolites in Allogeneic Stem Cell Transplantation Patients

Blood (2023) 142 (Supplement 1): 477.

https://doi.org/10.1182/blood-2023-172457

Published: 2023

Journal Articles

Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients

Blood (2022) 140 (Supplement 1): 7619–7621.

https://doi.org/10.1182/blood-2022-157423

Published: 2022

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr -Mutated Myelofibrosis

Blood (2022) 140 (Supplement 1): 10608–10610.

https://doi.org/10.1182/blood-2022-163048

Published: 2022

Journal Articles

Single Cell Transcriptomic Analysis of the Bone Marrow Microenvironment Uncovers a Role for Antigen Presentation Processes in MDS/AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Jennifer Rivière, Mark van der Garde, Judith S. Hecker, Michèle C. Buck, Florian Bassermann, Mareike Verbeek, Katharina S. Goetze

Blood (2022) 140 (Supplement 1): 2906–2907.

https://doi.org/10.1182/blood-2022-165255

Published: 2022

Journal Articles

Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Alessia Fraccaroli, Elena Stauffer, Katrin Koch, Klaus Hirschbühl, Stephan Breitkopf, Frank Ziemann, Heidrun Drolle, Maja Rothenberg-Thurley, Annika Maria Dufour, Klaus H. Metzeler, Michael von Bergwelt, Karsten Spiekermann, Andreas Hausmann, Christoph Schmid, Mareike Verbeek, Tobias Herold, Johanna Tischer

Blood (2022) 140 (Supplement 1): 4882–4883.

https://doi.org/10.1182/blood-2022-167299

Published: 2022

Journal Articles

Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML - Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI

Rama Al Hamed, Myriam Labopin, Wolfgang Bethge, Arnold Ganser, Arne Brecht, Johanna Tischer, Nicolaus Kröger, Donald Bunjes, Hermann Einsele, Mareike Verbeek, Igor Wolfgang Blau, Martin Kaufmann, Eolia Brissot, Ali Bazarbachi, Christoph Schmid, Alexandros Spyridonidis, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 10455–10457.

https://doi.org/10.1182/blood-2022-170244

Published: 2022

Journal Articles

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig, Matthias Stelljes, Verena I Gaidzik, Michael Lauseker, Oliver Kriege, Mareike Verbeek, Julia M. Unglaub, Felicitas Thol, Stefan W. Krause, Mathias Haenel, Charlotte Neuerburg, Vladan Vucinic, Christian Jehn, Julia Severmann, Maxi Wass, Lars Fransecky, Jens Chemnitz, Udo Holtick, Kerstin Schäfer-Eckart, Josephine Schröder, Sabrina Kraus, William Hermann Krüger, Ulrich Kaiser, Sebastian Scholl, Lea Henning, Guido Kobbe, Rainer Haas, Nael Alakel, Maximilian Alexander Röhnert, Katja Sockel, Maher Hanoun, Uwe Platzbecker, Tobias A. W. Holderried, Anke Morgner, Michael Heuser, Tim Sauer, Katharina S. Goetze, Eva Maria Wagner, Konstanze Döhner, Hartmut Döhner, Christoph Schliemann, Johannes Schetelig, Martin Bornhäuser, Ulrich Germing, Thomas Schroeder, Moritz Moritz Middeke

Blood (2021) 138 (Supplement 1): 33.

https://doi.org/10.1182/blood-2021-153440

Published: 2021

Journal Articles

Longitudinal Analysis of Gut Bacteriome, Mycobiome, Virome and Metabolome in Allogeneic Stem Cell Transplantation Reveals Susceptibility for Acute Graft-Versus-Host Disease

Blood (2021) 138 (Supplement 1): 332.

https://doi.org/10.1182/blood-2021-153026

Published: 2021

Journal Articles

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Robert Zeiser, MD, Andreas Burchert, MD, Claudia Lengerke, MD, Mareike Verbeek, Kristina Maas-Bauer, MD, Stephan Metzelder, MD, Silvia Spoerl, MD, Markus Ditschkowski, MD, Matyas Ecsedi, MD, Katja Sockel, MD, Francis Ayuk, MD, Ajib Salem, MD, Flore Sicre de Fontbrune, MD, Il-Kang Na, MD, Penter Livius, MD, Udo Holtick, MD PhD, Dominik Wolf, MD, Esther Schuler, MD, Everett Meyer, MD PhD, Petya Apostolova, MD, Hartmut Bertz, MD, Reinhard Marks, MD, Michael Lübbert, MD, Ralph Wäsch, MD, Christof Scheid, MD PhD, Friedrich Stölzel, MD, Rainer Ordemann, MD, Gesine Bug, MD, Guido Kobbe, MD, Omid Shah, MD, Robert S. Negrin, MD, Mats Brune, MD PhD, Alexandros Spyridonidis, MD PhD, Annette Schmitt-Graeff, MD, Walter J.F.M. van der Velden, MD PhD, Gerwin Huls, MD PhD, Stephan Mielke, MD, Goetz Ulrich Grigoleit, MD, Jurgen Kuball, MD PhD, Ryan P Flynn, PhD, Gabriele Ihorst, PhD, Jing Du, Bruce R. Blazar, MD, Renate Arnold, MD, Nicolaus Kröger, MD, Jakob R. Passweg, Joerg Halter, MD, Gérard Socié, MD PhD, Dietrich W. Beelen, Prof. Dr. MD, Christian Peschel, MD, Andreas Neubauer, Jürgen Finke, Justus Duyster, MD, Nikolas von Bubnoff, MD

Blood (2016) 128 (22): 4561.

https://doi.org/10.1182/blood.V128.22.4561.4561

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Enhancing the sequential flamsa-treosulfan conditioning regimen with venetoclax – first results from the multicenter flamsaclax Phase I/II trial

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.

Multicenter Phase II trial of enasidenib as maintenance treatment following allogeneic stem cell transplantation in IDH2-mutated myeloid neoplasms – the IDH2-post-allo-trial (NCT04522895)

The role of microbial metabolites in fecal microbiota transplantation in patients with acute gvhd of the gut

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Omitting Ciprofloxacin Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Does Not Result in Inferior Outcomes

Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes

Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Real-World Data Suggest Effectiveness of Allogeneic Mesenchymal Stromal (MSC-FFM) Cells in Ruxolitinib-Refractory Acute Graft-Versus-Host Disease

Bacterial and Bacteriophage Consortia Are Associated with Protective Intestinal Immuno-Modulatory Metabolites in Allogeneic Stem Cell Transplantation Patients

Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients

Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr -Mutated Myelofibrosis

Single Cell Transcriptomic Analysis of the Bone Marrow Microenvironment Uncovers a Role for Antigen Presentation Processes in MDS/AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation

Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML - Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Longitudinal Analysis of Gut Bacteriome, Mycobiome, Virome and Metabolome in Allogeneic Stem Cell Transplantation Reveals Susceptibility for Acute Graft-Versus-Host Disease

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only